500 related articles for article (PubMed ID: 20526762)
1. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
Taskinen MR; Barter PJ; Ehnholm C; Sullivan DR; Mann K; Simes J; Best JD; Hamwood S; Keech AC;
Diabetologia; 2010 Sep; 53(9):1846-55. PubMed ID: 20526762
[TBL] [Abstract][Full Text] [Related]
2. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC; Jenkins AJ; Li L; Zannino D; Mann KP; Best JD; Stuckey BG; Park K; Saltevo J; Keech AC;
Diabetologia; 2014 Nov; 57(11):2296-303. PubMed ID: 25149070
[TBL] [Abstract][Full Text] [Related]
3. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
[TBL] [Abstract][Full Text] [Related]
4. Sex-specific differences in blood lipids and lipid ratios in type 2 diabetic foot patients.
Yin S; Zhao P; Ai Z; Deng B; Jia W; Wang H; Zheng J
J Diabetes Investig; 2021 Dec; 12(12):2203-2211. PubMed ID: 34137504
[TBL] [Abstract][Full Text] [Related]
5. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
[TBL] [Abstract][Full Text] [Related]
6. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study.
Bruno G; Merletti F; Biggeri A; Bargero G; Prina-Cerai S; Pagano G; Cavallo-Perin P
Diabetologia; 2006 May; 49(5):937-44. PubMed ID: 16525840
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
Welsh C; Celis-Morales CA; Brown R; Mackay DF; Lewsey J; Mark PB; Gray SR; Ferguson LD; Anderson JJ; Lyall DM; Cleland JG; Jhund PS; Gill JMR; Pell JP; Sattar N; Welsh P
Circulation; 2019 Aug; 140(7):542-552. PubMed ID: 31216866
[TBL] [Abstract][Full Text] [Related]
8. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.
Parish S; Peto R; Palmer A; Clarke R; Lewington S; Offer A; Whitlock G; Clark S; Youngman L; Sleight P; Collins R;
Eur Heart J; 2009 Sep; 30(17):2137-46. PubMed ID: 19520708
[TBL] [Abstract][Full Text] [Related]
9. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
10. Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios.
Diaf M; Khaled BM; Sellam F
Libyan J Med; 2015; 10(1):27400. PubMed ID: 25959906
[TBL] [Abstract][Full Text] [Related]
11. Effects of gender, age and menopausal status on serum apolipoprotein concentrations.
Anagnostis P; Stevenson JC; Crook D; Johnston DG; Godsland IF
Clin Endocrinol (Oxf); 2016 Nov; 85(5):733-740. PubMed ID: 27086565
[TBL] [Abstract][Full Text] [Related]
12. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
[TBL] [Abstract][Full Text] [Related]
13. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.
Jiang R; Schulze MB; Li T; Rifai N; Stampfer MJ; Rimm EB; Hu FB
Diabetes Care; 2004 Aug; 27(8):1991-7. PubMed ID: 15277429
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Hiukka A; Leinonen E; Jauhiainen M; Sundvall J; Ehnholm C; Keech AC; Taskinen MR
Diabetologia; 2007 Oct; 50(10):2067-75. PubMed ID: 17653691
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study.
Bertrand C; Saulnier PJ; Potier L; Croyal M; Blanchard V; Gand E; Ragot S; Schneider F; Bocock O; Baillet-Blanco L; Velho G; Marre M; Roussel R; Rigalleau V; Hadjadj S; Mohammedi K;
Diabetologia; 2021 Mar; 64(3):668-680. PubMed ID: 33409569
[TBL] [Abstract][Full Text] [Related]
16. Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults.
Zheng S; Han T; Xu H; Zhou H; Ren X; Wu P; Zheng J; Wang L; Zhang M; Jiang Y; Chen Y; Qiu H; Liu W; Hu Y
BMJ Open; 2017 Jan; 7(1):e014038. PubMed ID: 28110289
[TBL] [Abstract][Full Text] [Related]
17. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH
Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
19. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
Diabetologia; 2009 Feb; 52(2):218-25. PubMed ID: 18972097
[TBL] [Abstract][Full Text] [Related]
20. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
